Abstract The HER2 amplicon on chromosome 17q is variable in size and occasionally includes Topoisomerase 2A (TOP2A) at 17q21-22. It has been suggested that TOP2 coamplification, not HER2 amplification on chromosome 17q11.2-12, is a useful predictive marker of response to anthracycline-based chemotherapy in breast cancer patients. Given the significant toxicities of anthracyclines, the detection methods of TOP2A gene amplifications have to be standardized. We determined TOP2A gene alterations using two different fluorescence in situ hybridization (FISH) DNA probes. HER2 amplifications were identified with the PathVysion TM probe. TOP2A status of 42 HER2 amplified breast cancers was tested by FISH with PathVysion TM covering 160 kb and DAKO pharm DX TM covering 228 kb of the TOP2A amplicon. TOP2A protein expression was tested by immunohistochemistry. Multiplex-ligation dependent probe amplification (MLPA) was performed retrospectively in cases showing discrepancies. TOP2A was amplified in 15 of 42 cases (35%) with DAKO pharm DX TM and in 11 of 42 cases (26%) with PathVysion TM . In all four discrepant cases, MLPA showed no TOP2A amplification, but instead amplification of an upstream region including HER2. TOP2A was deleted in the same seven of 42 carcinomas (17%) with both probes. TOP2A protein expression was detected in all 42 tumours (100%) with high intratumoral heterogeneity. TOP2A amplification rate depends on the length of the hybridized probes for the TOP2A locus. Because TOP2A, not HER2, is a target of anthracyclines, non-overlapping DNA probes should be used to evaluate any associations between such alterations and response to anthracycline-based chemotherapy.
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Introduction
Currently, anthracyclines represent the main adjuvant treatment of early stage breast cancer. Not all patients benefit from such treatment and these agents have significant toxicities. Evaluation of the TOP2A gene in HER2 positive breast cancer has been recently addressed as a predictor of the response to anthracycline-based chemotherapy [9, 20, 21] . HER2 positive patients with simultaneously amplified TOP2A gene were associated with longer survival and increased response to anthracycline-based chemotherapy than HER2 positive patients without TOP2A amplification [9, 14, 18, 21, 23] . HER2 expression alone does not alter anthracycline sensitivity. Furthermore, HER2 and TOP2A co-amplification predicts improved overall and disease free survival more reliably in breast cancer patients [1, 14] . Conversely, lack of TOP2A gene amplification (i.e. a normal gene status or a deletion of the TOP2A) has been associated with anthracycline resistance [1, 21, 23] .
HER2 is located on chromosome 17q11.2-12. In vivo and in vitro studies have shown that HER2 overexpression alone does not alter anthracycline sensitivity [11] . TOP2A at 17q21-22 is in close proximity to HER2, resulting in a proportion of HER2 amplified breast cancer cases also containing co-amplification of TOP2A [12, 13, 16] . Because TOP2A is a target of anthracyclines, it is possible that this gene, not HER2, is responsible for anthracycline responsiveness [21] .
Larger studies have shown that 33-60% of HER2 positive cancers contain concurrent TOP2A amplifications, while 20-42% are TOP2A deleted. According to some studies, TOP2A alterations are extremely rare in the absence of HER2 amplification, while others report a 10-20% TOP2A amplification or deletion rate in HER2 negative breast cancer [6, 10, 20, 21] . This wide variability may have different causes and is likely related to the fluorescence in situ hybridization (FISH) technology. Fluorescence or chromogenic labelled in situ hybridization technology (FISH, CISH) or immunohistochemistry (IHC) have been the choice of methods in many previous studies [1, 4-6, 14, 18, 20-23] . Numerical analysis of TOP2A gene alterations has been conducted in many studies in an analogous way as it is usually done in HER2 testing and a cut-off [2 TOP2A/CEP17 ratio was used to determine an amplified TOP2A status [5, 6, 14, 18, 21, 23] . Deletion of the TOP2A gene conversely has been set to different TOP2A/CEP17 ratios ranging from 0.5 to 1 [5-7, 14, 18, 20] .
In the current study, we addressed the question whether the rate of TOP2A amplification and deletion depends on the length of the FISH detection probes using different FISH probes (PathVysion TM and DAKO pharm DX TM ). Twenty of 42 patients had hormone receptor positive carcinomas (48%), 22 of 42 patients had hormone receptor negative carcinomas (52%). Tumours were graded according to the modified Bloom and Richardson grading system for invasive breast cancer [24] . Thirty-six carcinomas (86%) were poorly differentiated, and 6 cases (14%) were moderately differentiated.
Materials and methods

Patients
TOP2A immunohistochemistry
Protein expression was determined immunohistochemically on 2-lm thick paraffin embedded sections by using a mouse anti TOP2A monoclonal primary antibody (DAKO, DakoCytomation, Denmark A/S, Glostrup, clone: M7186, dilution: 1:400). The entire procedure was carried out on the Ventana Benchmark automated staining system by applying Ventana reagents. Pretreatment was performed by cooking with CC1-Buffer (Ventana) for 36 min at 95°C.
TOP2A antibody was detected by the iVIEW DAB detection kit and the signal was enhanced using the amplification kit.
As to stain intensity and specificity of TOP2A immunohistochemistry, we analysed normal breast tissue on large sections in a similar fashion as seen with MIB-1 or ER immunohistochemistry. Vessels and interstitial spaces were not stained, only nuclei in the ductulo-lobular units was stained. TOP2A immunohistochemistry was scored as follows: clear nuclear staining regardless of stain intensity was considered as positive. The extent of positive cells was estimated semi-quantitatively over the tumour area on intermediate power view (109 magnification) and was scored in a percentage.
TOP2A fluorescence in situ hybridisation
TOP2A gene status on 17q21-22 was determined by using two dual colour DNA probe kits and a three colour DNA probe kit (Fig. 1) . This dual colour probe hybridizes the TOP2A gene on 17q21-q22 labelled with spectrum orange. The DNA clones cover a total of 160 kb of the TOP2A amplicon on 17q21-q22. The centromer (CEP17) is hybridized with spectrum green on 17p11.1-q11.1.
Kit 2: TOP2A/HER2/CEP17 (PathVysion TM , Code Nr: 32-19095, Vysis, Abbott AG, Diagnostic Division Baar, Switzerland).
This three colour probe contains the HER2 Gene (17q11.2-q12, labelled with spectrum green), the CEP17 region (17p11.1-q11.1, labelled with spectrum aqua) and the TOP2A gene (17q21-q22, labelled with spectrum orange). The DNA clones cover a total of 160 kb of the TOP2A amplicon on 17q21-q22 and a total of 190 kb of the HER2 amplicon on 17q11.2-q12.
Kit 3: TOP2A/CEP17 (DAKO pharm DX TM , Code Nr.: K5333, DakoCytomation, Denmark A/S, Glostrup).
This dual probe contains a mixture of TOP2A gene and CEP17. The TOP2A gene is labelled with Texas Red, which covers a total of 228 kb of the TOP2A amplicon on 17q21-q22. The CEP17 is labelled with spectrum green and covers the region of 17p11.1-q11.1.
For all fluorescence in situ hybridization analyses, paraffin embedded sections of two micrometer thickness were used. All procedures for the FISH analyses were carried out by following the recommended protocol of the manufacturers. Probe mixes were hybridized at 37°C between 14 and 20 h, washed in Rapid-Wash-Solution I at 73°C for 5 min, Rapid-Wash-Solution II and H 2 O for 7 min, air dried and counterstained with DAPI. The analysis was done by using an Olympus computer guided fluorescence microscope (BX61). For each tumour case, a new haematoxylin and eosin (H&E) stain was available in order to identify the invasive tumour component.
Scoring of all FISH kits was performed according to the recommendations in the literature [1, 6, 21] . The absolute copy number of both CEP17 and TOP2A were counted and manually transferred into an excel data sheet. If gene copies were present in clusters, they were recorded as clusters. Following recommendation for clusters in the ASCO/CAP guidelines for HER2 testing, larger clusters were documented as equivalent of approximately 12-14 gene copies per cluster [26, 27] . Each FISH reaction was additionally documented on at least one digital photograph.
Deletion of TOP2A gene was defined as the presence of one gene copy in more than 90% of the examined area. Amplification of the TOP2A gene was defined as at least 6 gene copies in a minimum of 100 invasive tumour cells. As aneuploidy of higher grade was not a relevant feature in this cancer cohort, it was not necessary to measure TOP2A/ CEP17 ratio. TOP2A gene status was considered as normal if the gene copy number was at least 2 and did not exceed 5 gene copies.
Immunohistochemistry and FISH reactions were carried out by one technician (SB), the reactions were analysed and scored by one pathologist (ZV).
Multiplex-ligation dependent probe amplification (MLPA)
This assay was conducted retrospectively on those cases which revealed discrepant amplification status with the FISH probes. The test was performed as previously described using the P004-C1 chromosome 17 kit (MRCHolland, Amsterdam, The Netherlands) containing 3 TOP2A probes [15, 16] . All tests were performed on an ABI 9700 PCR machine (Applied Biosystems, Foster City, CA, USA) and fragment analyses were run on an ABI 3730 DNA Analyser (Applied Biosystems). Copy number ratios were analysed using Genemapper (Applied Biosystems) and Coffalyser software (MRC-Holland). For genes with more than one probe present in the kit, the mean of all the probe peaks of this gene in duplicate was calculated. A mean value below 0.7 was defined as loss, a value between 0.7-1.3 was defined as normal, 1.3-2.0 as gain and values [2.0 were defined as (high level) amplification, as established previously [3] .
Results
TOP2A immunohistochemistry
There was heterogeneous TOP2A positivity in all 42 carcinomas. In 4 of 42 cases (9.5%) immunopositivity was found in 10% of the tumour cells. In 38 of 42 cases (90.5%), immunopositive nuclei were detected in more than 10% of the tumour cells (on average 50-80%). There was no correlation between TOP2A immunopositivity and TOP2A copy number by FISH.
TOP2A and CEP17 fluorescence in situ hybridisation (Fig. 2) 
Kit 1 and 2 (PathVysion TM ):
The FISH analysis with the dual and the three colour probe kits resulted in completely identical results. CEP17 was diploid in 31 of 42 cases (74%) and aneuploid (3-4 gene copies) in 11 cases (26%). There was no monosomy or aneuploidy of higher grade ([ 4 copies) of CEP17 detected. TOP2A was diploid in 9 cases (21%), deletion was found in 7 cases (17%). Low-aneuploidy (3-5 gene copies) was present in 15 cases (36%). Amplification of the TOP2A was present in 11 cases (26%). Among the amplified cases, TOP2A copy number reached 6-8 in 4 tumours. TOP2a was present in smaller clusters in 7 other amplified cases.
Kit 3 (DAKO pharm DX TM ):
CEP17 was diploid in 33 of 42 cases (79%) and aneuploid (3-4 gene copies) in 8 cases (19%). Monosomy was detected in one case (2%). Aneuploidy of higher grade ([4 copies) of CEP17 was not detected. TOP2A was diploid in 8 of 42 cases (19%), deletion was found in 7 cases (17%). Low-aneuploidy (3-5 gene copies) was present in 12 cases (28%). Amplification of the TOP2A gene was present in 15 cases (36%). Among the amplified cases, TOP2A copy number was 6-8 in 6 cases, larger clusters or in more than 12 gene copies were detected in 9 cases.
Multiplex-ligation dependent probe amplification (MLPA)
The four cases with discrepant amplification status with the FISH probes, showed amplification of the HER2 gene, GRB7 and IKZF3 (one of the cases also RARA) but no amplification of the TOP2A gene with the MLPA methodology. The TOP2A copy number ratios of the four discrepant cases were 0.86, 1.07, 1.21 and 0.99.
FISH and IHC results are summarised in Table 1 .
Discussion
In our study, a discrepancy in the HER2/TOP2A coamplification status was observed in 4 of 42 patients using different TOP2A probes. TOP2A was amplified in 26% by PathVysion TM and in 35% using DAKO pharm TM probe. There was no difference in the detection rate of TOP2A gene deletion. Both probes identified 7 identical cases with TOP2A gene deletion. Deletion or amplification of the TOP2A gene did not show any correlation to TOP2A protein expression. All 42 tumours showed at least 10% nuclear TOP2A positivity.
The results of our study suggest that the difference in detection rate of TOP2A amplification is due to the different length of the DNA probes hybridising to the TOP2A region (17q21-q22). The DAKO pharm TM probe covers a total of 228 kb of the TOP2A region, while the Pathvysion TM probe envelops a shorter DNA segment of 160 kb. The external MPLA control could not detect amplification of the TOP2A gene in any on the four discrepant cases; however, the HER2 gene was amplified with this methodology. These results strongly imply that the larger TOP2A DNA probe most likely overlaps with the HER2 gene region and thus results in 'overdetection'.
Differential detection rate depending on the length of the mapping probe has also been identified by Jacobson et al., by using three different probes of Genome Systems covering three regions telomeric from the HER2 gene [7] . Jacobson et al. [7] reported that the TOP2A amplification rate varies from 23-46% depending on the length of the a Normal TOP2A status (2 gene copies). CEP17 is present in 2 copies, the HER2 gene in up to 10 gene copies. b Deletion of TOP2A gene: one copy of TOP2a, three copies of CEP17 (aneusomic), small clusters and up to 8 copies of the HER2 gene. c Amplification of TOP2A gene: TOP2a, three copies of CEP17 (aneusomic), small clusters and up to 8 copies of the HER2 gene hybridizing probe, which is very similar to our results. Interestingly, a differential TOP2A gene deletion was detected as well, ranging from 8 to 23% [7] . In our study, TOP2A gene deletion rate was found in 7 identical cases (17%), independently of the FISH probe. The length of the FISH probe apparently does not influence the detection of gene deletion.
Amplification rate of the TOP2A gene in HER2 amplified breast cancer has been reportedly as high as 35% on average varying from 7 to 50% [4, 6-10, 14, 20, 21] . The variable incidence of TOP2A aberrations is most likely due to heterogenous study populations, divergent cut-offs/ scoring systems as well as to the different specificity of the in situ hybridisation probes used for detection [2, 6, 20, 21] . Literature data are based on at least two different in situ hybridisation kits including fluorescent (FISH) and chromogenic (CISH) technology of three different companies (DAKO pharm TM , Pathvysion TM and ZymedÒ) [1, 4-6, 14, 18, 20-23, 25] .
As to scoring of TOP2A gene numeration, in most studies an analogous system to HER2 scoring has been applied using a cut-off [2 TOP2A/CEP17 to determine an amplified TOP2A status [5, 6, 14, 18, 21, 23] . However, in some earlier studies, TOP2A amplification was defined as a TOP2A/CEP17 ratio [1.5 [4, 7, 20] . When using the absolute copy number for TOP2A amplification, most studies set the cut-off of at least 6 TOP2A gene copies [1, 23] . The same is true for the definition of TOP2A gene allelic deletion in the literature. Cut-offs for deletion include different TOPAa/CEP17ratios ranging from \0.50, \0.70, \0.75, \0.8 to \1.0 [5-7, 14, 18, 20] .
In most studies, TOP2A gene amplification has been detected in a setting of co-amplification with the HER2 gene, but rarely in HER2 non-amplified patients [6, 20, 21] . The two genes are located on two distinct chromosomal regions and deletion of the TOP2A gene can commonly occur in the presence of HER2 amplification [7, 8] . HER2 gene amplification is often accompanied by co-amplification of several adjacent genes comprising 17q12-q21, e.g. TOP2A or RARA [12, 13, 16] . It is important to note, that both commercially available TOP2A FISH probes hybridize a DNA region, which is positioned approximately 679 kb in distance from the HER2 gene [17, 19] .
Intratumoral heterogeneity of TOP2A gene signals can give an additional explanation on conflicting literature data regarding the frequency of TOP2A gene alterations [7, 10] . The number of cells showing TOP2A gene alterations can be largely influenced by the material used for the study: cell lines, imprint preparations, tissue microarrays or whole tissue sections can result in different percentages of TOP2A altered cells due to the heterogeneous distribution of the altered cells [7, 10] . As described by Jarvinen et al. [7, 10] , TOP2A amplified and deleted cells can be found within the same tumour. Such heterogeneity was seen in up to 14% of breast cancer samples [7, 10] . Interestingly, the critical evaluation of our breast cancer samples revealed intratumoral heterogeneity of TOP2A alterations in most breast carcinomas. We did not see mixed patterns of deleted or amplified cells, but rather a mixture of amplified and normal cells or deleted and normal cells within the same tumour. This is in contrast to the HER2 gene amplification in our cohort, which was in general a homogenous finding over the whole tissue sections.
Therapeutic benefit of adjuvant anthracycline containing regiments at HER2 and TOP2A positive breast cancer patients has been controversial. Depending on the study cohort and diagnostic criteria for TOP2A status determination, predictive and prognostic value of HER2 and/or TOP2A amplification for treatment response could be confirmed or questioned in several previous mostly retrospective studies [1, 2, 14, 18, [21] [22] [23] 25] . Tubbs et al. [25] reported earlier in a prospective tissue microarray based study that HER2 gene status and not TOP2A gene alterations are prognostic in anthracycline treated patients. Data from another prospective recent trial by Press et al. [21] demonstrate that TOP2A co-amplification but not HER2 amplification is the clinically predictive marker for response to anthracycline-based chemotherapy.
This discrepancy cannot be explained by technical issues, because DNA probe kits from PathVysion TM and the same cut-offs for signal interpretation were used in both studies [21, 25] . It is more likely that the interpretation of a heterogeneous distribution of TOP2A alterations has caused divergent results in both tissue microarray based studies [21, 25] .
A recent meta-analysis from five randomised adjuvant trials suggests that not only patients with HER2 gene amplified tumours, but also those with non-amplified HER2 and normal TOP2A status can benefit from anthracyclinebased adjuvant therapy [15] . In this meta-analysis, Leo et al. [15] propose the need for increased standardisation in TOP2A testing by FISH methodology due to suboptimal reproducibility.
The biological relevance of TOP2A protein overexpression is controversial. Arriola et al. [1, 14] reported that TOP2A protein overexpression correlates to high proliferation fraction, hormone receptor positivity and either to HER2 or to basal phenotype. Moelans et al. [12, 13, 16] found an association between TOP2A overexpression and TOP2A gene amplification but not with gene deletion. According to our data, TOP2A protein was expressed in all breast cancer cases independently of any other factors.
In summary, our data clearly underscore the relevance of appropriate standardisation of the FISH technology and probes for TOP2A testing with predictive purposes. Additional testing, for example MLPA technology to doublecheck amplification status, is a possibility to be addressed in future studies.
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